D. Ross Camidge

Also affiliated with University of Colorado Anschutz Medical Campus, University of Colorado Denver

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 19 papers. Top paper: “Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions”.

Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions

Neuro-Oncology(2022)10.1093/neuonc/noac118

N/A

3.5DataRank · unranked

197 citations

Nayan Lamba, Manmeet S. Ahluwalia, Kenneth Aldape, Adrienne Boire, Priscilla K. Brastianos +20 more

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Nature Medicine(2020)10.1038/s41591-019-0716-8

N/A

0.898DataRank · unranked

397 citations

Jeffrey W. Clark, Jared Weiss, Sai‐Hong Ignatius Ou, D. Ross Camidge, Benjamin Solomon +16 more

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7

N/A

0.769DataRank · unranked

168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2024.10.010

N/A

0.693DataRank · unranked

19 citations

D. Ross Camidge, Paul Wheatley‐Price, William J. Phillips

The intersection between cannabis and cancer in the United States

Critical Reviews in Oncology/Hematology(2012)10.1016/j.critrevonc.2011.09.008

N/A

0.631DataRank · unranked

66 citations

Cindy L. O’Bryant, D. Ross Camidge, Antonio Jimeno, Daniel W. Bowles

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0231

N/A

0.587DataRank · unranked

49 citations

Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson +23 more

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-4084

N/A

0.574DataRank · unranked

45 citations

Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura +15 more

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC

npj Precision Oncology(2021)10.1038/s41698-021-00231-x

N/A

0.492DataRank · unranked

11 citations

Tejas Patil, Anh T. Le, Kurtis D. Davies, Peter Brzeskiewicz, Hala Nijmeh +5 more

Targeting ALK, ROS1, and BRAF Kinases

Journal of Thoracic Oncology(2012)10.1097/jto.0b013e31826df05e

N/A

0.360DataRank · unranked

10 citations

D. Ross Camidge, Robert C. Doebele

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00510

N/A

0.208DataRank · unranked

3 citations

Jose M. Pacheco, Anastasios Dimou, W. Thomas Purcell, Candice Rossi, Paul A. Bunn +4 more

Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports(2025)10.1016/j.jtocrr.2025.100870

N/A

0.104DataRank · unranked

1 citations

Alyse Staley, Benjamin A. Yoder, Sean J. Iwamoto, Vida Alami, Erin L. Schenk +4 more

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

Journal of Clinical Oncology(2024)10.1200/jco.23.02668

N/A

0DataRank · unranked

49 citations

Emily Miao, Lillian A. Boe, Tejas Patil, Brandon S. Imber, Nathaniel J. Myall +19 more

Data from Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

(2023)10.1158/1078-0432.c.6520385

N/A

0DataRank · unranked

0 citations

David S. Boss, D. Ross Camidge, Carolyn D. Britten, Jeffrey A. Engelman, Edward B. Garon +9 more

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100637

N/A

0DataRank · unranked

8 citations

Alyse Staley, Yunan Nie, M Sakamoto, Margaret Stalker, James Jurica +17 more

Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center

Frontiers in Oncology(2025)10.3389/fonc.2025.1546500

N/A

0DataRank · unranked

0 citations

Sama L. Kareem, Bradley R. Corr, Christopher H. Lieu, Breelyn A. Wilky, S. Lindsey Davis +9 more

Data from Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

(2023)10.1158/1078-0432.c.6520385.v1

N/A

0DataRank · unranked

0 citations

David S. Boss, D. Ross Camidge, Carolyn D. Britten, Jeffrey A. Engelman, Edward B. Garon +9 more

First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors

Cancers(2023)10.3390/cancers16010091

N/A

0DataRank · unranked

11 citations

Jodi Kagihara, Bradley R. Corr, S. Lindsey Davis, Christopher H. Lieu, Sunnie S. Kim +14 more

Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer

Cell(2020)10.1016/j.cell.2020.09.052

N/A

0DataRank · unranked

11 citations

Erin L. Schenk, D. Ross Camidge

Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.11.013

N/A

0DataRank · unranked

2 citations

Amber M. Johnson, Raphael A. Nemenoff, Elena W.Y. Hsieh, Andrea Abeyta Osypuk, Adrie Van Bokhoven +4 more